The company said on June 3, 2024 it entered into a Stock and Asset Purchase Agreement with Becton, Dickinson and Company to sell its Critical Care product group for $4,200,000,000 in cash.

8-KRegulation FD DisclosureFiled Jun 3, 2024Period of report Jun 3, 2024Summary published (UTC) Oct 26, 2026

Key points

AI summary

The company said on June 3, 2024 it entered into a Stock and Asset Purchase Agreement with Becton, Dickinson and Company to sell its Critical Care product group for $4,200,000,000 in cash.
Edwards said on June 3, 2024 it is no longer pursuing the previously announced spin-off of Critical Care, in connection with the purchase agreement.
Edwards said it will use the after-tax cash proceeds to fund strategic growth investments. It also said the impact to adjusted earnings per share (EPS) in 2024 would be immaterial if the deal closes as expected.
The company said it expects the transaction to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions, including the receipt of required antitrust and foreign investment approvals.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Critical Care Product Group to Be Sold to BD for $4,200,000,000 in Cash

The company said on June 3, 2024 it entered into a Stock and Asset Purchase Agreement with Becton, Dickinson and Company to sell its Critical Care product group for $4,200,000,000 in cash.

Source · Based on the filing body and exhibits

Critical Care Spin-Off No Longer Being Pursued

Edwards said on June 3, 2024 it is no longer pursuing the previously announced spin-off of Critical Care, in connection with the purchase agreement.

Source · Based on the filing body and exhibits

Use of Sale Proceeds and Adjusted EPS Impact

Edwards said it will use the after-tax cash proceeds to fund strategic growth investments. It also said the impact to adjusted earnings per share (EPS) in 2024 would be immaterial if the deal closes as expected.

Source · Based on the filing body and exhibits

Expected Closing Timing and Closing Conditions

The company said it expects the transaction to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions, including the receipt of required antitrust and foreign investment approvals.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.